ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

OXB Oxford Biomedica Plc

328.00
28.00 (9.33%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica Plc LSE:OXB London Ordinary Share GB00BDFBVT43 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  28.00 9.33% 328.00 325.50 330.00 350.00 303.00 304.00 1,285,192 16:35:22
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medicinal Chems,botanicl Pds 139.99M -45.16M -0.4676 -6.95 313.89M
Oxford Biomedica Plc is listed in the Medicinal Chems,botanicl Pds sector of the London Stock Exchange with ticker OXB. The last closing price for Oxford Biomedica was 300p. Over the last year, Oxford Biomedica shares have traded in a share price range of 164.40p to 473.00p.

Oxford Biomedica currently has 96,580,639 shares in issue. The market capitalisation of Oxford Biomedica is £313.89 million. Oxford Biomedica has a price to earnings ratio (PE ratio) of -6.95.

Oxford Biomedica Share Discussion Threads

Showing 22276 to 22295 of 26775 messages
Chat Pages: Latest  903  902  901  900  899  898  897  896  895  894  893  892  Older
DateSubjectAuthorDiscuss
09/10/2022
14:45
I think £10 sale price in 12 months looks like a real stretch at current share price jezmundo, maybe you are a future sweep winner! Hopefully you are correct as the share looks heavily oversold.
catch007
09/10/2022
13:31
My future financial plan has the remainder of my holding sold in the next 12 months. I am not looking to reach the stars but would expect a 10 pound sale minimum. H and Co, Keep up the good work.
jezmundo
09/10/2022
10:07
Apparently Bill Gates was in the news again yesterday repeating the WHO line that the malaria vaccine manufacture should be a global affair and not all eggs in one basket.

Quite how that stacks up against Serum's plans for a future 2bn dose vaccine factory I'm not sure.

I'm guessing that Serum, having made one fortune out of coronavirus, and now that we've established globally a precedent for locking populations down for long periods of time, are seeing an opportunity to do much better in the "next" pandemic...

harry s truman
09/10/2022
09:58
I'm not sure what this is but it was released on Friday



May just be a regulatory formality, but it does say human use (not investigational).

harry s truman
09/10/2022
03:01
GigabitYou're wasting your breath with Cummings and the zealots.....which is why you started your own thread in the first place. As I said before you come out with reasoned arguements........which get slated by the zealot cretins If Cummings thinks that being heavily indebted is good....I'm sure that OXB will oblige with more...... they'll probably have no choice.
badger60
08/10/2022
23:05
I'm glad to see that some places still call last orders at the traditional 10:30.
blinddarts
08/10/2022
22:46
Gigabit, the whole market crashed on Friday on US data.
youre arguments always negative, not seen a single positive one. why dont you look into how the company positioning as a global leader in the lenti vector. have you read aboit the follicular leukemia? or you read and ignored it!
this company is becoming more american and away from the rubbish and destructive UK investors and their hedge funds that short to cause pain without thinking about the damage they cause. bet you people in these hedge funds never think cancer can knock on their doors or doors of people they care for. peob you think the same.
I am long this company and I repeat my view, in the US it will be worth $3-$5 bln.

qnq
08/10/2022
20:58
All of the above is 'potential', but you won't contemplate that will you. I believe they decided they didn't want so much cash as quickly as they had arranged, and if the market is concerned about cash, then rearranging it to deal with that at a modest extra cost is worth it.
dominiccummings
08/10/2022
20:38
and no longer mates rates!


Malaria and Flu vaccines Last For One Year therefore ongoing revenue. The analysts and market will love that.

marcusl2
08/10/2022
18:24
It's not really old news though is it Jez?

I think the real cash position in OXB at the moment is about £30m. Pretty soon we get another £58m (ish) to add to that and yet OXB see a need for $50m more from Oaktree with an option for another $25m again.

That's an awful lot of cash for a company which did its big Boston spend in H1 and said that H2 had 90% of its projected work in and would be close to breaking even.

They must want the cash for something and I've shot some ideas off in various directions. Marcus evidently thinks there will be some spend in kitting out the fallow half of OXB with the production suites big enough for the 2,000 litre bioreactors which we currently have none of, but they do talk about in the presentation video.

I agree that we need to wait and see, but Serum are definitely up to something in the UK in reserving one of our bioreactors and entering a joint venture on a fill and finish line here.

harry s truman
08/10/2022
18:06
But is the RNS good news? A USD 85 million loan has been replaced with a USD 50 million loan at a 25% higher interest rate. Furthermore USD 35 million of the original loan has been repaid to Oaktree effectively leaving OXB with a USD 50 million debt and USD 15 million with which to repay it, plus interest of course which will total around USD 15-20 million over the four years. There is also a further option to borrow another USD 25 million which would, probably, cover the cost of meeting the Homology put option sometime between now and 2025. So no reduction in debt and an increase in interest payments. Is that really good news?
gigabit
08/10/2022
13:15
That article is from August, it's old news, i know you are deep in, but relax and be patient.
jezmundo
08/10/2022
12:29
That's a splendid find Marcus!
dominiccummings
08/10/2022
12:17
Serum Institute of India (SII) may make “flu or malaria vaccines” at the Oxford Biomedica facility at Oxbox near Oxford, said SII CEO Adar Poonawalla.



SII is building a future pandemic facility, which will have an annual capacity of 2 bn doses

Serum Institute of India | Malaria vaccine | Flu






A confirmation RNS would surely give the share price quite a boost!

marcusl2
08/10/2022
11:07
Aye gigabit, but that takes into account the traditional OXB share price response to a good RNS. Up in the morning, close down!
dominiccummings
08/10/2022
10:51
A picture painting a thousand words there Plutonian.

From a patient's point of view a significantly smaller chance of a storm reaction, but I guess it will still be the doctor's choice and in the US (biggest market?) brand incentives are perfectly legal.

harry s truman
08/10/2022
09:24
DC - that certainly was an impressive market response - once they had crunched the numbers it was back to square one.
gigabit
08/10/2022
06:42
Fwiw...FIXX (Homology)

3 year share price...........USD 26.00+
....................today...........USD 1.46

badger60
08/10/2022
06:30
Yep....another good point, OXB are tied into shelling out for the final 20% of Homology in (now) less than 3 years. Not much incentive to do well....... guaranteed pay off. Have you noticed how all the US Homology Phd brothers are joining hedge funds after managing and then leaving companies like Homology?
badger60
08/10/2022
02:14
I see they've ripped off mugs at 20 PPS on the OBD new issue........it was trading at 10pps 2 months ago. Just a matter of time and it'll be back down there again.
badger60
Chat Pages: Latest  903  902  901  900  899  898  897  896  895  894  893  892  Older

Your Recent History

Delayed Upgrade Clock